Advertisement

Androgen Replacement Therapy in Hypogonadal Men

  • Jonas Čeponis
  • Ronald S. Swerdloff
  • Christina Wang
Chapter
Part of the Contemporary Endocrinology book series (COE)

Abstract

Androgen replacement therapy should be considered for all hypogonadal men with persistent low serum testosterone levels and symptoms of testosterone deficiency. Before commencement of replacement, contraindications to androgen treatment should be identified. In hypogonadal men, androgens improve sexual function, energy and mood, increase muscle mass and strength, as well as bone mineral density. Androgen therapy can be tailored to each patient’s needs and preferences. There are many new androgen delivery systems introduced in the past few years and many more are in development. Selective androgen receptor modulators may have the potential of optimizing beneficial effects while minimizing potential adverse effects. In older men, monitoring of prostate dysfunction and red cell indexes is necessary and important. With care, androgens can be used efficaciously and with minimal potential side effects.

Keywords

Testosterone deficiency Testosterone replacement Benefits versus risks Contraindications to testosterone therapy Testosterone delivery systems Monitoring of treatment responses 

Notes

Acknowledgements

This work was supported by UCLA CTSI Grant UL1TR000124 to Los Angeles Biomedical Research Institute and Harbor UCLA Medical Center (CW) and NICHD Contract HHSN27520130024I (RSS and CW) and the Baltic American Freedom Foundation Research Scholar Program (JC).

References

  1. 1.
    Baillargeon J, Urban RJ, Ottenbacher KJ, Pierson KS, Goodwin JS. Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Int Med. 2013;173(15):1465–6.CrossRefGoogle Scholar
  2. 2.
    Nguyen CP, Hirsch MS, Moeny D, Kaul S, Mohamoud M, Joffe HV. Testosterone and “age-related hypogonadism”–FDA concerns. N Engl J Med. 2015;373(8):689–91.PubMedCrossRefGoogle Scholar
  3. 3.
    Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363(2):123–35.PubMedCrossRefGoogle Scholar
  4. 4.
    Cunningham GR, Stephens-Shields AJ, Rosen RC, Wang C, Ellenberg SS, Matsumoto AM, et al. Association of sex hormones with sexual function, vitality, and physical function of symptomatic older men with low testosterone levels at baseline in the testosterone trials. J Clin Endocrinol Metab. 2015;100(3):1146–55.PubMedCrossRefGoogle Scholar
  5. 5.
    Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536–59.PubMedCrossRefGoogle Scholar
  6. 6.
    Taieb J, Mathian B, Millot F, Patricot MC, Mathieu E, Queyrel N, et al. Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. Clin Chem. 2003;49(8):1381–95.PubMedCrossRefGoogle Scholar
  7. 7.
    Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine society position statement. J Clin Endocrinol Metab. 2007;92(2):405–13.PubMedCrossRefGoogle Scholar
  8. 8.
    Wang C, Catlin DH, Demers LM, Starcevic B, Swerdloff RS. Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab. 2004;89(2):534–43.PubMedCrossRefGoogle Scholar
  9. 9.
    Vesper HW, Botelho JC. Standardization of testosterone measurements in humans. J Steroid Biochem Mol Biol. 2010.Google Scholar
  10. 10.
    Vesper HW, Botelho JC, Shacklady C, Smith A, Myers GL. CDC project on standardizing steroid hormone measurements. Steroids. 2008;73(13):1286–92.PubMedCrossRefGoogle Scholar
  11. 11.
    Vesper HW, Thienpont LM. Traceability in laboratory medicine. Clin Chem. 2009;55(6):1067–75.PubMedCrossRefGoogle Scholar
  12. 12.
    Steinberger E, Ayala C, Hsi B, Smith KD, Rodriguez-Rigau LJ, Weidman ER, et al. Utilization of commercial laboratory results in management of hyperandrogenism in women. Endocr Pract Official J Am Coll Endocrinol Am Assoc Clin Endocrinol. 1998;4(1):1–10.Google Scholar
  13. 13.
    Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84(10):3666–72.PubMedCrossRefGoogle Scholar
  14. 14.
    O’Connor S, Baker HW, Dulmanis A, Hudson B. The measurement of sex steroid binding globulin by differential ammonium sulphate precipitation. J Steroid Biochem. 1973;4(4):331–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Cumming DC, Wall SR. Non-sex hormone-binding globulin-bound testosterone as a marker for hyperandrogenism. J Clin Endocrinol Metab. 1985;61(5):873–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Sinha-Hikim I, Arver S, Beall G, Shen R, Guerrero M, Sattler F, et al. The use of a sensitive equilibrium dialysis method for the measurement of free testosterone levels in healthy, cycling women and in human immunodeficiency virus-infected women. J Clin Endocrinol Metab. 1998;83(4):1312–8.PubMedGoogle Scholar
  17. 17.
    Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363(2):123–35.PubMedCrossRefGoogle Scholar
  18. 18.
    Zakharov MN, Bhasin S, Travison TG, Xue R, Ulloor J, Vasan RS, et al. A multi-step, dynamic allosteric model of testosterone’s binding to sex hormone binding globulin. Mol Cell Endocrinol. 2015;399:190–200.PubMedCrossRefGoogle Scholar
  19. 19.
    Ohlsson C, Wallaschofski H, Lunetta KL, Stolk L, Perry JR, Koster A, et al. Genetic determinants of serum testosterone concentrations in men. PLoS Genet. 2011;7(10):e1002313.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Vermeulen A. Clinical review 24: androgens in the aging male. J Clin Endocrinol Metab. 1991;73(2):221–4.PubMedCrossRefGoogle Scholar
  21. 21.
    Vermeulen A. Decreased androgen levels and obesity in men. Ann Med. 1996;28(1):13–5.PubMedCrossRefGoogle Scholar
  22. 22.
    Glass AR, Swerdloff RS, Bray GA, Dahms WT, Atkinson RL. Low serum testosterone and sex-hormone-binding-globulin in massively obese men. J Clin Endocrinol Metab. 1977;45(6):1211–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Sodergard R, Backstrom T, Shanbhag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem. 1982;16(6):801–10.PubMedCrossRefGoogle Scholar
  24. 24.
    de Ronde W, van der Schouw YT, Pols HA, Gooren LJ, Muller M, Grobbee DE, et al. Calculation of bioavailable and free testosterone in men: a comparison of 5 published algorithms. Clin Chem. 2006;52(9):1777–84.PubMedCrossRefGoogle Scholar
  25. 25.
    Ly LP, Sartorius G, Hull L, Leung A, Swerdloff RS, Wang C, et al. Accuracy of calculated free testosterone formulae in men. Clin Endocrinol. 2010;73:382–8.CrossRefGoogle Scholar
  26. 26.
    Sartorius G, Ly LP, Sikaris K, McLachlan R, Handelsman DJ. Predictive accuracy and sources of variability in calculated free testosterone estimates. Ann Clin Biochem. 2009;46(Pt 2):137–43.PubMedCrossRefGoogle Scholar
  27. 27.
    Rosner W. Errors in the measurement of plasma free testosterone. J Clin Endocrinol Metab. 1997;82(6):2014–5.PubMedCrossRefGoogle Scholar
  28. 28.
    Winters SJ, Kelley DE, Goodpaster B. The analog free testosterone assay: are the results in men clinically useful? Clin Chem. 1998;44(10):2178–82.PubMedGoogle Scholar
  29. 29.
    Miller KK, Rosner W, Lee H, Hier J, Sesmilo G, Schoenfeld D, et al. Measurement of free testosterone in normal women and women with androgen deficiency: comparison of methods. J Clin Endocrinol Metab. 2004;89(2):525–33.PubMedCrossRefGoogle Scholar
  30. 30.
    Khosla S, Riggs BL. Androgens, estrogens, and bone turnover in men. J Clin Endocrinol Metab. 2003;88(5):2352–3.PubMedCrossRefGoogle Scholar
  31. 31.
    Finkelstein JS, Lee H, Burnett-Bowie SA, Pallais JC, Yu EW, Borges LF, et al. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013;369(11):1011–22.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Burnett-Bowie SA, McKay EA, Lee H, Leder BZ. Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels. J Clin Endocrinol Metab. 2009;94(12):4785–92.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Liu PY, Caterson ID, Grunstein RR, Handelsman DJ. Androgens, obesity, and sleep-disordered breathing in men. Endocrinol Metab Clin North Am. 2007;36(2):349–63.PubMedCrossRefGoogle Scholar
  34. 34.
    Burris AS, Banks SM, Carter CS, Davidson JM, Sherins RJ. A long-term, prospective study of the physiologic and behavioral effects of hormone replacement in untreated hypogonadal men. J Androl. 1992;13(4):297–304.PubMedGoogle Scholar
  35. 35.
    Davidson JM, Camargo CA, Smith ER. Effects of androgen on sexual behavior in hypogonadal men. J Clin Endocrinol Metab. 1979;48(6):955–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Skakkebaek NE, Bancroft J, Davidson DW, Warner P. Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study. Clin Endocrinol. 1981;14(1):49–61.CrossRefGoogle Scholar
  37. 37.
    Wang C, Eyre DR, Clark R, Kleinberg D, Newman C, Iranmanesh A, et al. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men—a clinical research center study. J Clin Endocrinol Metab. 1996;81(10):3654–62.PubMedGoogle Scholar
  38. 38.
    Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab. 2000;85(8):2839–53.PubMedGoogle Scholar
  39. 39.
    Hajjar RR, Kaiser FE, Morley JE. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab. 1997;82(11):3793–6.PubMedCrossRefGoogle Scholar
  40. 40.
    Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Lenrow DA, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab. 1999;84(8):2647–53.PubMedGoogle Scholar
  41. 41.
    Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P. Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study. J Sex Med. 2014;11(3):840–56.PubMedCrossRefGoogle Scholar
  42. 42.
    Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, Moncada I, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diab Care. 2011;34(4):828–37.CrossRefGoogle Scholar
  43. 43.
    Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016;374(7):611–24.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Buvat J, Montorsi F, Maggi M, Porst H, Kaipia A, Colson MH, et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). J Sex Med. 2011;8(1):284–93.PubMedCrossRefGoogle Scholar
  45. 45.
    Basaria S, Harman SM, Travison TG, Hodis H, Tsitouras P, Budoff M, et al. Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels: a randomized clinical trial. JAMA. 2015;314(6):570–81.PubMedCrossRefGoogle Scholar
  46. 46.
    Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001;281(6):E1172–81.PubMedGoogle Scholar
  47. 47.
    Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab. 2006;91(11):4335–43.PubMedCrossRefGoogle Scholar
  48. 48.
    Dabbs JM Jr. Salivary testosterone measurements in behavioral studies. Ann N Y Acad Sci. 1993;694:177–83.PubMedCrossRefGoogle Scholar
  49. 49.
    O’Connor DB, Archer J, Hair WM, Wu FC. Activational effects of testosterone on cognitive function in men. Neuropsychologia. 2001;39(13):1385–94.PubMedCrossRefGoogle Scholar
  50. 50.
    Bagatell CJ, Heiman JR, Matsumoto AM, Rivier JE, Bremner WJ. Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men. J Clin Endocrinol Metab. 1994;79(2):561–7.PubMedGoogle Scholar
  51. 51.
    Anderson RA, Bancroft J, Wu FC. The effects of exogenous testosterone on sexuality and mood of normal men. J Clin Endocrinol Metab. 1992;75(6):1503–7.PubMedGoogle Scholar
  52. 52.
    Anderson RA, Martin CW, Kung AW, Everington D, Pun TC, Tan KC, et al. 7Alpha-methyl-19-nortestosterone maintains sexual behavior and mood in hypogonadal men. J Clin Endocrinol Metab. 1999;84(10):3556–62.PubMedGoogle Scholar
  53. 53.
    Wang C, Alexander G, Berman N, Salehian B, Davidson T, McDonald V, et al. Testosterone replacement therapy improves mood in hypogonadal men—a clinical research center study. J Clin Endocrinol Metab. 1996;81(10):3578–83.PubMedGoogle Scholar
  54. 54.
    Tong SF, Ng CJ, Lee BC, Lee VK, Khoo EM, Lee EG, et al. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. Asian J Androl. 2012;14(4):604–11.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Pope HG Jr, Amiaz R, Brennan BP, Orr G, Weiser M, Kelly JF, et al. Parallel-group placebo-controlled trial of testosterone gel in men with major depressive disorder displaying an incomplete response to standard antidepressant treatment. J Clin Psychopharmacol. 2010;30(2):126–34.PubMedCrossRefGoogle Scholar
  56. 56.
    Alexander GM, Swerdloff RS, Wang C, Davidson T, McDonald V, Steiner B, et al. Androgen-behavior correlations in hypogonadal men and eugonadal men. II. Cognitive abilities. Horm Behav. 1998;33(2):85–94.PubMedCrossRefGoogle Scholar
  57. 57.
    Boone KB, Swerdloff RS, Miller BL, Geschwind DH, Razani J, Lee A, et al. Neuropsychological profiles of adults with Klinefelter syndrome. J Int Neuropsychol Soc. 2001;7(4):446–56.PubMedCrossRefGoogle Scholar
  58. 58.
    Patwardhan AJ, Eliez S, Bender B, Linden MG, Reiss AL. Brain morphology in Klinefelter syndrome: extra X chromosome and testosterone supplementation. Neurology. 2000;54(12):2218–23.PubMedCrossRefGoogle Scholar
  59. 59.
    Cherrier MM, Anawalt BD, Herbst KL, Amory JK, Craft S, Matsumoto AM, et al. Cognitive effects of short-term manipulation of serum sex steroids in healthy young men. J Clin Endocrinol Metab. 2002;87(7):3090–6.PubMedCrossRefGoogle Scholar
  60. 60.
    Janowsky JS, Chavez B, Orwoll E. Sex steroids modify working memory. J Cogn Neurosci. 2000;12(3):407–14.PubMedCrossRefGoogle Scholar
  61. 61.
    Janowsky JS, Oviatt SK, Orwoll ES. Testosterone influences spatial cognition in older men. Behav Neurosci. 1994;108(2):325–32.PubMedCrossRefGoogle Scholar
  62. 62.
    Kenny AM, Bellantonio S, Gruman CA, Acosta RD, Prestwood KM. Effects of transdermal testosterone on cognitive function and health perception in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci. 2002;57(5):M321–5.PubMedCrossRefGoogle Scholar
  63. 63.
    Yaffe K, Lui LY, Zmuda J, Cauley J. Sex hormones and cognitive function in older men. J Am Geriatr Soc. 2002;50(4):707–12.PubMedCrossRefGoogle Scholar
  64. 64.
    Greendale GA, Edelstein S, Barrett-Connor E. Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo study. J Bone Miner Res. 1997;12(11):1833–43.PubMedCrossRefGoogle Scholar
  65. 65.
    Khosla S, Melton LJ 3rd, Atkinson EJ, O’Fallon WM, Klee GG, Riggs BL. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab. 1998;83(7):2266–74.PubMedGoogle Scholar
  66. 66.
    Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab. 1995;80(12):3689–98.PubMedGoogle Scholar
  67. 67.
    Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med. 1994;331(16):1056–61.PubMedCrossRefGoogle Scholar
  68. 68.
    Carani C, Qin K, Simoni M, Faustini-Fustini M, Serpente S, Boyd J, et al. Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med. 1997;337(2):91–5.PubMedCrossRefGoogle Scholar
  69. 69.
    Khosla S, Melton LJ 3rd, Atkinson EJ, O’Fallon WM. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab. 2001;86(8):3555–61.PubMedCrossRefGoogle Scholar
  70. 70.
    Khosla S, Riggs BL, Atkinson EJ, Oberg AL, Mavilia C, Del MF, et al. Relationship of estrogen receptor genotypes to bone mineral density and to rates of bone loss in men. J Clin Endocrinol Metab. 2004;89(4):1808–16.PubMedCrossRefGoogle Scholar
  71. 71.
    Finkelstein JS, Lee H, Leder BZ, Burnett-Bowie SA, Goldstein DW, Hahn CW, et al. Gonadal steroid-dependent effects on bone turnover and bone mineral density in men. J Clin Invest. 2016;126(3):1114–25.PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Colvard DS, Eriksen EF, Keeting PE, Wilson EM, Lubahn DB, French FS, et al. Identification of androgen receptors in normal human osteoblast-like cells. Proc Natl Acad Sci U S A. 1989;86(3):854–7.PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Cawthon PM, Schousboe JT, Harrison SL, Ensrud KE, Black D, Cauley JA, et al. Sex hormones, sex hormone binding globulin, and vertebral fractures in older men. Bone. 2016;84:271–8.PubMedPubMedCentralCrossRefGoogle Scholar
  74. 74.
    Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab. 1996;81(12):4358–65.PubMedGoogle Scholar
  75. 75.
    Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 1997;82(8):2386–90.PubMedCrossRefGoogle Scholar
  76. 76.
    Kenny AM, Prestwood KM, Raisz LG. Short-term effects of intramuscular and transdermal testosterone on bone turnover, prostate symptoms, cholesterol, and hematocrit in men over age 70 with low testosterone levels. Endocr Res. 2000;26(2):153–68.PubMedCrossRefGoogle Scholar
  77. 77.
    Tenover JL. Male senescence. In: Wang C, editor. Male reproductive function. Boston: Kluwer Academic Publishers; 1999. p. 139–56.CrossRefGoogle Scholar
  78. 78.
    Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab. 2000;85(8):2670–7.PubMedGoogle Scholar
  79. 79.
    Ishizaka K, Suzuki M, Kageyama Y, Kihara K, Yoshida K. Bone mineral density in hypogonadal men remains low after long-term testosterone replacement. Asian J Androl. 2002;4(2):117–21.PubMedGoogle Scholar
  80. 80.
    Medras M, Jankowska EA, Rogucka E. Effects of long-term testosterone substitutive therapy on bone mineral content in men with hypergonadotrophic hypogonadism. Andrologia. 2001;33(1):47–52.PubMedCrossRefGoogle Scholar
  81. 81.
    Kenny AM, Kleppinger A, Annis K, Rathier M, Browner B, Judge JO, et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. J Am Geriatr Soc. 2010;58(6):1134–43.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf). 2005;63(3):280–93.PubMedCrossRefGoogle Scholar
  83. 83.
    Corona G, Giagulli VA, Maseroli E, Vignozzi L, Aversa A, Zitzmann M, et al. THERAPY OF ENDOCRINE DISEASE: testosterone supplementation and body composition: results from a meta-analysis study. Eur J Endocrinol. 2016;174(3):R99–116.PubMedCrossRefGoogle Scholar
  84. 84.
    Brodsky IG, Balagopal P, Nair KS. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men—a clinical research center study. J Clin Endocrinol Metab. 1996;81(10):3469–75.PubMedGoogle Scholar
  85. 85.
    Sinha-Hikim I, Artaza J, Woodhouse L, Gonzalez-Cadavid N, Singh AB, Lee MI, et al. Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. Am J Physiol Endocrinol Metab. 2002;283(1):E154–64.PubMedCrossRefGoogle Scholar
  86. 86.
    Bhasin S, Storer TW, Berman N, Yarasheski KE, Clevenger B, Phillips J, et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab. 1997;82(2):407–13.PubMedGoogle Scholar
  87. 87.
    Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM, Bremner WJ, et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab. 2005;90(3):1502–10.PubMedCrossRefGoogle Scholar
  88. 88.
    Clague JE, Wu FC, Horan MA. Difficulties in measuring the effect of testosterone replacement therapy on muscle function in older men. Int J Androl. 1999;22(4):261–5.PubMedCrossRefGoogle Scholar
  89. 89.
    Srinivas-Shankar U, Roberts SA, Connolly MJ, O’Connell MD, Adams JE, Oldham JA, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2010;95(2):639–50.PubMedCrossRefGoogle Scholar
  90. 90.
    Basaria S, Collins L, Dillon EL, Orwoll K, Storer TW, Miciek R, et al. The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. J Gerontol A Biol Sci Med Sci. 2013;68(1):87–95.PubMedCrossRefGoogle Scholar
  91. 91.
    Srinivas-Shankar U, Roberts SA, Connolly MJ, O’Connell MD, Adams JE, Oldham JA, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2010;95(2):639–50.PubMedCrossRefGoogle Scholar
  92. 92.
    Hoyos CM, Yee BJ, Phillips CL, Machan EA, Grunstein RR, Liu PY. Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnoea: a randomised placebo-controlled trial. Eur J Endocrinol. 2012;167(4):531–41.PubMedCrossRefGoogle Scholar
  93. 93.
    Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016;374(7):611–24.PubMedPubMedCentralCrossRefGoogle Scholar
  94. 94.
    Vanttinen T, Blomqvist M, Hakkinen K. Development of body composition, hormone profile, physical fitness, general perceptual motor skills, soccer skills and on-the-ball performance in soccer-specific laboratory test among adolescent soccer players. J Sports Sci Med. 2010;9(4):547–56.PubMedPubMedCentralGoogle Scholar
  95. 95.
    Frederiksen L, Hojlund K, Hougaard DM, Mosbech TH, Larsen R, Flyvbjerg A, et al. Testosterone therapy decreases subcutaneous fat and adiponectin in aging men. European journal of endocrinology/ European Federation of Endocrine Societies. 2012;166(3):469–76.CrossRefGoogle Scholar
  96. 96.
    Aversa A, Bruzziches R, Francomano D, Spera G, Lenzi A. Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome. J Endocrinol Invest. 2010;33(11):776–83.PubMedCrossRefGoogle Scholar
  97. 97.
    Marin P, Holmang S, Jonsson L, Sjostrom L, Kvist H, Holm G, et al. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord. 1992;16(12):991–7.PubMedGoogle Scholar
  98. 98.
    Neto WK, Gama EF, Rocha LY, Ramos CC, Taets W, Scapini KB, et al. Effects of testosterone on lean mass gain in elderly men: systematic review with meta-analysis of controlled and randomized studies. Age (Dordr). 2015;37(1):9742.PubMedCrossRefGoogle Scholar
  99. 99.
    Dhindsa S, Ghanim H, Batra M, Kuhadiya ND, Abuaysheh S, Sandhu S, et al. Insulin Resistance and Inflammation in Hypogonadotropic Hypogonadism and Their Reduction After Testosterone Replacement in Men With Type 2 Diabetes. Diabetes Care. 2016;39(1):82–91.PubMedCrossRefGoogle Scholar
  100. 100.
    Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf). 2010;73(5):602–12.PubMedCrossRefGoogle Scholar
  101. 101.
    Gianatti EJ, Dupuis P, Hoermann R, Strauss BJ, Wentworth JM, Zajac JD, et al. Effect of testosterone treatment on glucose metabolism in men with type 2 diabetes: a randomized controlled trial. Diabetes Care. 2014;37(8):2098–107.PubMedCrossRefGoogle Scholar
  102. 102.
    Heufelder AE, Saad F, Bunck MC, Gooren L. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl. 2009;30(6):726–33.PubMedCrossRefGoogle Scholar
  103. 103.
    Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. European journal of endocrinology/ European Federation of Endocrine Societies. 2006;154(6):899–906.CrossRefGoogle Scholar
  104. 104.
    Francomano D, Lenzi A, Aversa A. Effects of five-year treatment with testosterone undecanoate on metabolic and hormonal parameters in ageing men with metabolic syndrome. Int J Endocrinol. 2014;2014:527470.PubMedPubMedCentralCrossRefGoogle Scholar
  105. 105.
    Grossmann M. Low testosterone in men with type 2 diabetes: significance and treatment. J Clin Endocrinol Metab. 2011;96(8):2341–53.PubMedCrossRefGoogle Scholar
  106. 106.
    Aversa A, Bruzziches R, Francomano D, Rosano G, Isidori AM, Lenzi A, et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. The journal of sexual medicine. 2010;7(10):3495–503.PubMedCrossRefGoogle Scholar
  107. 107.
    Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab. 2004;89(7):3313–8.PubMedCrossRefGoogle Scholar
  108. 108.
    Wang C, Jackson G, Jones TH, Matsumoto AM, Nehra A, Perelman MA, et al. Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care. 2011;34(7):1669–75.PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    Bagatell CJ, Heiman JR, Matsumoto AM, Rivier JE, Bremner WJ. Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men. J Clin Endocrinol Metab. 1994;79(2):561–7.PubMedGoogle Scholar
  110. 110.
    Arver S, Dobs AS, Meikle AW, Caramelli KE, Rajaram L, Sanders SW, et al. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men. Clin Endocrinol. 1997;47(6):727–37.CrossRefGoogle Scholar
  111. 111.
    Dobs AS, Bachorik PS, Arver S, Meikle AW, Sanders SW, Caramelli KE, et al. Interrelationships among lipoprotein levels, sex hormones, anthropometric parameters, and age in hypogonadal men treated for 1 year with a permeation-enhanced testosterone transdermal system. J Clin Endocrinol Metab. 2001;86(3):1026–33.PubMedGoogle Scholar
  112. 112.
    Friedl KE, Hannan CJ Jr, Jones RE, Plymate SR. High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Metabolism. 1990;39(1):69–74.PubMedCrossRefGoogle Scholar
  113. 113.
    Fernandez-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95(6):2560–75.PubMedCrossRefGoogle Scholar
  114. 114.
    Singh AB, Hsia S, Alaupovic P, Sinha-Hikim I, Woodhouse L, Buchanan TA, et al. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J Clin Endocrinol Metab. 2002;87(1):136–43.PubMedCrossRefGoogle Scholar
  115. 115.
    Arora S, Patra SK, Saini R. HDL-A molecule with a multi-faceted role in coronary artery disease. Clinica chimica acta; international journal of clinical chemistry. 2015;452:66–81.PubMedCrossRefGoogle Scholar
  116. 116.
    Barter PJ, Rye KA. Targeting High-Density Lipoproteins to Reduce Cardiovascular Risk: what Is the Evidence? Clinical therapeutics. 2015.Google Scholar
  117. 117.
    Phillips GB, Pinkernell BH, Jing TY. The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb. 1994;14(5):701–6.PubMedCrossRefGoogle Scholar
  118. 118.
    Zhao SP, Li XP. The association of low plasma testosterone level with coronary artery disease in Chinese men. Int J Cardiol. 1998;63(2):161–4.PubMedCrossRefGoogle Scholar
  119. 119.
    Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab. 2008;93(1):68–75.PubMedCrossRefGoogle Scholar
  120. 120.
    Khaw KT, Dowsett M, Folkerd E, Bingham S, Wareham N, Luben R, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation. 2007;116(23):2694–701.PubMedCrossRefGoogle Scholar
  121. 121.
    Corona G, Rastrelli G, Monami M, Guay A, Buvat J, Sforza A, et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. European journal of endocrinology/ European Federation of Endocrine Societies. 2011;165(5):687–701.CrossRefGoogle Scholar
  122. 122.
    Barrett-Connor E, Khaw KT. Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation. 1988;78(3):539–45.PubMedGoogle Scholar
  123. 123.
    Simon D, Charles MA, Nahoul K, Orssaud G, Kremski J, Hully V, et al. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: the Telecom Study. J Clin Endocrinol Metab. 1997;82(2):682–5.PubMedGoogle Scholar
  124. 124.
    Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR. Low serum testosterone and mortality in male veterans. Arch Intern Med. 2006;166(15):1660–5.PubMedCrossRefGoogle Scholar
  125. 125.
    Jaffe MD. Effect of testosterone cypionate on postexercise ST segment depression. Br Heart J. 1977;39(11):1217–22.PubMedPubMedCentralCrossRefGoogle Scholar
  126. 126.
    Wu SZ, Weng XZ. Therapeutic effects of an androgenic preparation on myocardial ischemia and cardiac function in 62 elderly male coronary heart disease patients. Chin Med J. 1993;106(6):415–8.PubMedGoogle Scholar
  127. 127.
    English KM, Mandour O, Steeds RP, Diver MJ, Jones TH, Channer KS. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J. 2000;21(11):890–4.PubMedCrossRefGoogle Scholar
  128. 128.
    Rosano GM, Leonardo F, Pagnotta P, Pelliccia F, Panina G, Cerquetani E, et al. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation. 1999;99(13):1666–70.PubMedCrossRefGoogle Scholar
  129. 129.
    Webb CM, McNeill JG, Hayward CS, de Zeigler D, Collins P. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation. 1999;100(16):1690–6.PubMedCrossRefGoogle Scholar
  130. 130.
    Thompson PD, Ahlberg AW, Moyna NM, Duncan B, Ferraro-Borgida M, White CM, et al. Effect of intravenous testosterone on myocardial ischemia in men with coronary artery disease. Am Heart J. 2002;143(2):249–56.PubMedCrossRefGoogle Scholar
  131. 131.
    Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363(2):109–22.PubMedPubMedCentralCrossRefGoogle Scholar
  132. 132.
    Vigen R, O’Donnell CI, Baron AE, Grunwald GK, Maddox TM, Bradley SM, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829–36.PubMedCrossRefGoogle Scholar
  133. 133.
    Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab. 2012;97(6):2050–8.PubMedCrossRefGoogle Scholar
  134. 134.
    Shores MM, Biggs ML, Arnold AM, Smith NL, Longstreth WT Jr, Kizer JR, et al. Testosterone, dihydrotestosterone, and incident cardiovascular disease and mortality in the cardiovascular health study. J Clin Endocrinol Metab. 2014;99(6):2061–8.PubMedPubMedCentralCrossRefGoogle Scholar
  135. 135.
    Baillargeon J, Urban RJ, Kuo YF, Ottenbacher KJ, Raji MA, Du F, et al. Risk of myocardial infarction in older men receiving testosterone therapy. Ann Pharmacother. 2014;48(9):1138–44.PubMedPubMedCentralCrossRefGoogle Scholar
  136. 136.
    Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS ONE. 2014;9(1):e85805.PubMedPubMedCentralCrossRefGoogle Scholar
  137. 137.
    Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 2013;11:108.PubMedPubMedCentralCrossRefGoogle Scholar
  138. 138.
    Corona G, Maseroli E, Rastrelli G, Isidori AM, Sforza A, Mannucci E, et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf. 2014;13(10):1327–51.PubMedCrossRefGoogle Scholar
  139. 139.
    Corona GG, Rastrelli G, Maseroli E, Sforza A, Maggi M. Testosterone replacement therapy and cardiovascular risk: a review. World J Men’s Health. 2015;33(3):130–42.CrossRefGoogle Scholar
  140. 140.
    Albert SG, Morley JE. Testosterone therapy, association with age, initiation and mode of therapy with cardiovascular events: a systematic review. Clin Endocrinol (Oxf). 2016.Google Scholar
  141. 141.
    Goodman N, Guay A, Dandona P, Dhindsa S, Faiman C, Cunningham GR. American association of clinical endocrinologists and American college of endocrinology position statement on the association of testosterone and cardiovascular risk. Endocr Pract Official J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2015;21(9):1066–73.Google Scholar
  142. 142.
    Behre HM, Bohmeyer J, Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol. 1994;40(3):341–9.CrossRefGoogle Scholar
  143. 143.
    Meikle AW, Arver S, Dobs AS, Adolfsson J, Sanders SW, Middleton RG, et al. Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system. Urology. 1997;49(2):191–6.PubMedCrossRefGoogle Scholar
  144. 144.
    Hildreth KL, Barry DW, Moreau KL, Vande Griend J, Meacham RB, Nakamura T, et al. Effects of testosterone and progressive resistance exercise in healthy, highly functioning older men with low-normal testosterone levels. J Clin Endocrinol Metab. 2013;98(5):1891–900.PubMedPubMedCentralCrossRefGoogle Scholar
  145. 145.
    Del Fabbro E, Garcia JM, Dev R, Hui D, Williams J, Engineer D, et al. Testosterone replacement for fatigue in hypogonadal ambulatory males with advanced cancer: a preliminary double-blind placebo-controlled trial. Support Care Cancer. 2013;21(9):2599–607.PubMedCrossRefGoogle Scholar
  146. 146.
    Tan WS, Low WY, Ng CJ, Tan WK, Tong SF, Ho C, et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU Int. 2013;111(7):1130–40.PubMedCrossRefGoogle Scholar
  147. 147.
    Kohn TP, Mata DA, Ramasamy R, Lipshultz LI. Effects of testosterone replacement therapy on lower urinary tract symptoms: a systematic review and meta-analysis. Eur Urol. 2016.Google Scholar
  148. 148.
    Handelsman DJ. The safety of androgens: prostate and cardiovascular disease. In: Wang C, editor. Male reproductive function. Boston: Kluwer Academic Publishers; 1999. p. 173–89.CrossRefGoogle Scholar
  149. 149.
    Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol. 2004;172(3):920–2.PubMedCrossRefGoogle Scholar
  150. 150.
    Page ST, Hirano L, Gilchriest J, Dighe M, Amory JK, Marck BT, et al. Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy. J Urol. 2011;186(1):191–7.PubMedPubMedCentralCrossRefGoogle Scholar
  151. 151.
    Calado RT, Yewdell WT, Wilkerson KL, Regal JA, Kajigaya S, Stratakis CA, et al. Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. Blood. 2009;114(11):2236–43.PubMedPubMedCentralCrossRefGoogle Scholar
  152. 152.
    Bar C, Huber N, Beier F, Blasco MA. Therapeutic effect of androgen therapy in a mouse model of aplastic anemia produced by short telomeres. Haematologica. 2015;100(10):1267–74.PubMedPubMedCentralCrossRefGoogle Scholar
  153. 153.
    Townsley DM, Dumitriu B, Liu D, Biancotto A, Weinstein B, Chen C, et al. Danazol treatment for telomere diseases. N Engl J Med. 2016;374(20):1922–31.PubMedPubMedCentralCrossRefGoogle Scholar
  154. 154.
    Rencricca NJ, Solomon J, Fimian WJ Jr, Howard D, Rizzoli V, Stohlman F Jr. The effect of testosterone on erythropoiesis. Scand J Haematol. 1969;6(6):431–6.PubMedCrossRefGoogle Scholar
  155. 155.
    Bachman E, Travison TG, Basaria S, Davda MN, Guo W, Li M, et al. Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point. J Gerontol A Biol Sci Med Sci. 2014;69(6):725–35.PubMedCrossRefGoogle Scholar
  156. 156.
    Guo W, Bachman E, Li M, Roy CN, Blusztajn J, Wong S, et al. Testosterone administration inhibits hepcidin transcription and is associated with increased iron incorporation into red blood cells. Aging Cell. 2013;12(2):280–91.PubMedPubMedCentralCrossRefGoogle Scholar
  157. 157.
    Bhasin S, Woodhouse L, Casaburi R, Singh AB, Mac RP, Lee M, et al. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab. 2005;90(2):678–88.PubMedCrossRefGoogle Scholar
  158. 158.
    Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, Bhasin S. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab. 2008;93(3):914–9.PubMedCrossRefGoogle Scholar
  159. 159.
    Delorimier AA, Gordan GS, Lowe RC, Carbone JV. Methyltestosterone, related steroids, and liver function. Arch Intern Med. 1965;116:289–94.PubMedCrossRefGoogle Scholar
  160. 160.
    Nadell J, Kosek J. Peliosis hepatis. Twelve cases associated with oral androgen therapy. Arch Pathol Lab Med. 1977;101(8):405–10.PubMedGoogle Scholar
  161. 161.
    Stout M, Tew GA, Doll H, Zwierska I, Woodroofe N, Channer KS, et al. Testosterone therapy during exercise rehabilitation in male patients with chronic heart failure who have low testosterone status: a double-blind randomized controlled feasibility study. Am Heart J. 2012;164(6):893–901.PubMedCrossRefGoogle Scholar
  162. 162.
    Matsumoto AM, Sandblom RE, Schoene RB, Lee KA, Giblin EC, Pierson DJ, et al. Testosterone replacement in hypogonadal men: effects on obstructive sleep apnoea, respiratory drives, and sleep. Clin Endocrinol. 1985;22(6):713–21.CrossRefGoogle Scholar
  163. 163.
    Liu PY, Swerdloff RS, Christenson PD, Handelsman DJ, Wang C. Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis. Lancet. 2006;367(9520):1412–20.PubMedCrossRefGoogle Scholar
  164. 164.
    Snyder PJ, Lawrence DA. Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab. 1980;51(6):1335–9.PubMedCrossRefGoogle Scholar
  165. 165.
    Sokol RZ, Palacios A, Campfield LA, Saul C, Swerdloff RS. Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. Fertil Steril. 1982;37(3):425–30.PubMedCrossRefGoogle Scholar
  166. 166.
    Zhang GY, Gu YQ, Wang XH, Cui YG, Bremner WJ. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. J Androl. 1998;19(6):761–8.PubMedGoogle Scholar
  167. 167.
    Behre HM, Abshagen K, Oettel M, Hubler D, Nieschlag E. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. Eur J Endocrinol Eur Fed Endocr Soc. 1999;140(5):414–9.CrossRefGoogle Scholar
  168. 168.
    Nieschlag E, Buchter D, Von Eckardstein S, Abshagen K, Simoni M, Behre HM. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men. Clin Endocrinol. 1999;51(6):757–63.CrossRefGoogle Scholar
  169. 169.
    Morgentaler A, Dobs AS, Kaufman JM, Miner MM, Shabsigh R, Swerdloff RS, et al. Long acting testosterone undecanoate therapy in men with hypogonadism: results of a pharmacokinetic clinical study. J Urol. 2008;180(6):2307–13.PubMedCrossRefGoogle Scholar
  170. 170.
    Wang C, Harnett M, Dobs AS, Swerdloff RS. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial. J Androl. 2010;31(5):457–65.PubMedCrossRefGoogle Scholar
  171. 171.
    Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab. 1999;84(10):3469–78.PubMedGoogle Scholar
  172. 172.
    Wang C, Nieschlag E, Swerdloff RS, Behre H, Hellstrom WJ, Gooren LJ, et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male. 2009;12(1):5–12.PubMedCrossRefGoogle Scholar
  173. 173.
    Bhasin S, Swerdloff RS, Steiner B, Peterson MA, Meridores T, Galmirini M, et al. A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10–11 weeks in hypogonadal men. J Clin Endocrinol Metab. 1992;74(1):75–83.PubMedGoogle Scholar
  174. 174.
    Amory JK, Anawalt BD, Blaskovich PD, Gilchriest J, Nuwayser ES, Matsumoto AM. Testosterone release from a subcutaneous, biodegradable microcapsule formulation (Viatrel) in hypogonadal men. J Androl. 2002;23(1):84–91.PubMedCrossRefGoogle Scholar
  175. 175.
    Bagchus WM, Hust R, Maris F, Schnabel PG, Houwing NS. Important effect of food on the bioavailability of oral testosterone undecanoate. Pharmacotherapy. 2003;23(3):319–25.PubMedCrossRefGoogle Scholar
  176. 176.
    Schnabel PG, Bagchus W, Lass H, Thomsen T, Geurts TB. The effect of food composition on serum testosterone levels after oral administration of Andriol testocaps. Clin Endocrinol. 2007;66(4):579–85.Google Scholar
  177. 177.
    Nieschlag E, Mauss J, Coert A, Kicovic P. Plasma androgen levels in men after oral administration of testosterone or testosterone undecanoate. Acta Endocrinol (Copenh). 1975;79(2):366–74.PubMedGoogle Scholar
  178. 178.
    Schurmeyer T, Wickings EJ, Freischem CW, Nieschlag E. Saliva and serum testosterone following oral testosterone undecanoate administration in normal and hypogonadal men. Acta Endocrinol (Copenh). 1983;102(3):456–62.PubMedGoogle Scholar
  179. 179.
    Legros JJ, Meuleman EJ, Elbers JM, Geurts TB, Kaspers MJ, Bouloux PM. Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. Eur J Endocrinol Eur Fed Endocr Soc. 2009;160(5):821–31.CrossRefGoogle Scholar
  180. 180.
    Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, Aleman A, Lock TM, Bosch JL, et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA. 2008;299(1):39–52.PubMedCrossRefGoogle Scholar
  181. 181.
    Gooren LJ. A ten-year safety study of the oral androgen testosterone undecanoate. J Androl. 1994;15(3):212–5.PubMedGoogle Scholar
  182. 182.
    Yin A, Alfadhli E, Htun M, Dudley R, Faulkner S, Hull L, et al. Dietary fat modulates the testosterone pharmacokinetics of a new self-emulsifying formulation of oral testosterone undecanoate in hypogonadal men. J Androl. 2012;33(6):1282–90.PubMedPubMedCentralCrossRefGoogle Scholar
  183. 183.
    Yin AY, Htun M, Swerdloff RS, Diaz-Arjonilla M, Dudley RE, Faulkner S, et al. Reexamination of pharmacokinetics of oral testosterone undecanoate in hypogonadal men with a new self-emulsifying formulation. J Androl. 2012;33(2):190–201.PubMedCrossRefGoogle Scholar
  184. 184.
    Cunningham GR, Cordero E, Thornby JI. Testosterone replacement with transdermal therapeutic systems. Physiological serum testosterone and elevated dihydrotestosterone levels. JAMA. 1989;261(17):2525–30.PubMedCrossRefGoogle Scholar
  185. 185.
    Findlay JC, Place V, Snyder PJ. Treatment of primary hypogonadism in men by the transdermal administration of testosterone. J Clin Endocrinol Metab. 1989;68(2):369–73.PubMedCrossRefGoogle Scholar
  186. 186.
    Brocks DR, Meikle AW, Boike SC, Mazer NA, Zariffa N, Audet PR, et al. Pharmacokinetics of testosterone in hypogonadal men after transdermal delivery: influence of dose. J Clin Pharmacol. 1996;36(8):732–9.PubMedCrossRefGoogle Scholar
  187. 187.
    Meikle AW, Arver S, Dobs AS, Sanders SW, Rajaram L, Mazer NA. Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site—a clinical research center study. J Clin Endocrinol Metab. 1996;81(5):1832–40.PubMedGoogle Scholar
  188. 188.
    Meikle AW, Mazer NA, Moellmer JF, Stringham JD, Tolman KG, Sanders SW, et al. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. J Clin Endocrinol Metab. 1992;74(3):623–8.PubMedGoogle Scholar
  189. 189.
    Layton JB, Li D, Meier CR, Sharpless JL, Sturmer T, Jick SS, et al. Testosterone lab testing and initiation in the United Kingdom and the United States, 2000 to 2011. J Clin Endocrinol Metab. 2014;99(3):835–42.PubMedPubMedCentralCrossRefGoogle Scholar
  190. 190.
    Swerdloff RS, Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab. 2000;85(12):4500–10.PubMedGoogle Scholar
  191. 191.
    Swerdloff RS, Pak Y, Wang C, Liu PY, Bhasin S, Gill TM, et al. Serum testosterone (T) level variability in T gel-treated older hypogonadal men: treatment monitoring implications. J Clin Endocrinol Metab. 2015;100(9):3280–7.PubMedPubMedCentralCrossRefGoogle Scholar
  192. 192.
    Muram D, Ni X. Utility of a single serum testosterone measurement to determine response to topical testosterone replacement in hypogonadal men. Curr Med Res Opin. 2015;1–24.Google Scholar
  193. 193.
    Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, et al. Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clin Endocrinol. 2001;54(6):739–50.CrossRefGoogle Scholar
  194. 194.
    Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 2004;89(5):2085–98.PubMedCrossRefGoogle Scholar
  195. 195.
    Satonin DK, Ni X, Mitchell MI, Joly H, Muram D, Small DS. Amount of testosterone on laundered clothing after use of testosterone topical 2% solution by healthy male volunteers. J Sex Med. 2016;13(2):187–93.PubMedCrossRefGoogle Scholar
  196. 196.
    Muram D, Melby T. Alles Kingshill E. Skin reactions in a phase 3 study of a testosterone topical solution applied to the axilla in hypogonadal men. Curr Med Res Opin. 2012;28(5):761–6.PubMedCrossRefGoogle Scholar
  197. 197.
    Schaison GNK, Couzinet B. Percutaneous dihydrotestosterone (DHT) treatment. In: Nieschlag EBH, editor. Testosterone: action deficiency, substitution. Berlin: Springer; 1990. p. 155–64.CrossRefGoogle Scholar
  198. 198.
    de Lignieres B. Transdermal dihydrotestosterone treatment of ‘andropause’. Ann Med. 1993;25(3):235–41.PubMedCrossRefGoogle Scholar
  199. 199.
    Kunelius P, Lukkarinen O, Hannuksela ML, Itkonen O, Tapanainen JS. The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. J Clin Endocrinol Metab. 2002;87(4):1467–72.PubMedCrossRefGoogle Scholar
  200. 200.
    Ly LP, Jimenez M, Zhuang TN, Celermajer DS, Conway AJ, Handelsman DJ. A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. J Clin Endocrinol Metab. 2001;86(9):4078–88.PubMedCrossRefGoogle Scholar
  201. 201.
    Wang C, Iranmanesh A, Berman N, McDonald V, Steiner B, Ziel F, et al. Comparative pharmacokinetics of three doses of percutaneous dihydrotestosterone gel in healthy elderly men—a clinical research center study. J Clin Endocrinol Metab. 1998;83(8):2749–57.PubMedGoogle Scholar
  202. 202.
    Wang C, Swerdloff RS. Should the nonaromatizable androgen dihydrotestosterone be considered as an alternative to testosterone in the treatment of the andropause? J Clin Endocrinol Metab. 2002;87(4):1462–6.PubMedCrossRefGoogle Scholar
  203. 203.
    Idan A, Griffiths KA, Harwood DT, Seibel MJ, Turner L, Conway AJ, et al. Long-term effects of dihydrotestosterone treatment on prostate growth in healthy, middle-aged men without prostate disease: a randomized, placebo-controlled trial. Ann Intern Med. 2010;153(10):621–32.PubMedCrossRefGoogle Scholar
  204. 204.
    Rogol AD, Tkachenko N, Bryson N. NatestoTM, a novel testosterone nasal gel, normalizes androgen levels in hypogonadal men. Andrology. 2016;4(1):46–54.PubMedCrossRefGoogle Scholar
  205. 205.
    Wang C, Swerdloff R, Kipnes M, Matsumoto AM, Dobs AS, Cunningham G, et al. New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men. J Clin Endocrinol Metab. 2004;89(8):3821–9.PubMedCrossRefGoogle Scholar
  206. 206.
    Dinsmore WW, Wyllie MG. The long-term efficacy and safety of a testosterone mucoadhesive buccal tablet in testosterone-deficient men. BJU Int. 2012;110(2):162–9.PubMedCrossRefGoogle Scholar
  207. 207.
    Handelsman DJ, Conway AJ, Boylan LM. Pharmacokinetics and pharmacodynamics of testosterone pellets in man. J Clin Endocrinol Metab. 1990;71(1):216–22.PubMedCrossRefGoogle Scholar
  208. 208.
    Handelsman DJ, Mackey MA, Howe C, Turner L, Conway AJ. An analysis of testosterone implants for androgen replacement therapy. Clin Endocrinol. 1997;47(3):311–6.CrossRefGoogle Scholar
  209. 209.
    Kelleher S, Turner L, Howe C, Conway AJ, Handelsman DJ. Extrusion of testosterone pellets: a randomized controlled clinical study. Clin Endocrinol. 1999;51(4):469–71.CrossRefGoogle Scholar
  210. 210.
    Mohler ML, Bohl CE, Jones A, Coss CC, Narayanan R, He Y, et al. Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. J Med Chem. 2009;52(12):3597–617.PubMedCrossRefGoogle Scholar
  211. 211.
    Cummings DE, Kumar N, Bardin CW, Sundaram K, Bremner WJ. Prostate-sparing effects in primates of the potent androgen 7alpha-methyl-19-nortestosterone: a potential alternative to testosterone for androgen replacement and male contraception. J Clin Endocrinol Metab. 1998;83(12):4212–9.PubMedGoogle Scholar
  212. 212.
    Kumar N, Didolkar AK, Monder C, Bardin CW, Sundaram K. The biological activity of 7 alpha-methyl-19-nortestosterone is not amplified in male reproductive tract as is that of testosterone. Endocrinology. 1992;130(6):3677–83.PubMedGoogle Scholar
  213. 213.
    Anderson RA, Wallace AM, Sattar N, Kumar N, Sundaram K. Evidence for tissue selectivity of the synthetic androgen 7α-Methyl-19-Nortestosterone in hypogonadal men. J Clin Endocrinol Metab. 2003;88(6):2784–93.PubMedCrossRefGoogle Scholar
  214. 214.
    von Eckardstein S, Noe G, Brache V, Nieschlag E, Croxatto H, Alvarez F, et al. A clinical trial of 7 alpha-methyl-19-nortestosterone implants for possible use as a long-acting contraceptive for men. J Clin Endocrinol Metab. 2003;88(11):5232–9.CrossRefGoogle Scholar
  215. 215.
    Attardi BJ, Hild SA, Reel JR. Dimethandrolone undecanoate: a new potent orally active androgen with progestational activity. Endocrinology. 2006;147(6):3016–26.PubMedCrossRefGoogle Scholar
  216. 216.
    Surampudi P, Page ST, Swerdloff RS, Nya-Ngatchou JJ, Liu PY, Amory JK, et al. Single, escalating dose pharmacokinetics, safety and food effects of a new oral androgen dimethandrolone undecanoate in man: a prototype oral male hormonal contraceptive. Andrology. 2014;2(4):579–87.PubMedPubMedCentralCrossRefGoogle Scholar
  217. 217.
    Edwards JP, Zhi L, Pooley CL, Tegley CM, West SJ, Wang MW, et al. Preparation, resolution, and biological evaluation of 5-aryl-1, 2-dihydro-5H-chromeno[3,4-f]quinolines: potent, orally active, nonsteroidal progesterone receptor agonists. J Med Chem. 1998;41(15):2779–85.PubMedCrossRefGoogle Scholar
  218. 218.
    Hamann LG, Higuchi RI, Zhi L, Edwards JP, Wang XN, Marschke KB, et al. Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines. J Med Chem. 1998;41(4):623–39.PubMedCrossRefGoogle Scholar
  219. 219.
    Dalton JT, Taylor RP, Mohler ML, Steiner MS. Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer. Curr Opin Support Palliat Care. 2013;7(4):345–51.PubMedCrossRefGoogle Scholar
  220. 220.
    Dobs AS, Boccia RV, Croot CC, Gabrail NY, Dalton JT, Hancock ML, et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol. 2013;14(4):335–45.PubMedPubMedCentralCrossRefGoogle Scholar
  221. 221.
    Dalton JT, Barnette KG, Bohl CE, Hancock ML, Rodriguez D, Dodson ST, et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle. 2011;2(3):153–61.PubMedPubMedCentralCrossRefGoogle Scholar
  222. 222.
    Swerdloff RS, Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab. 2000;85(12):4500–10.PubMedGoogle Scholar
  223. 223.
    Sokol RZ, Palacios A, Campfield LA, Saul C, Swerdloff RS. Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. Ferti Steril. 1982;37(3):425–30.CrossRefGoogle Scholar
  224. 224.
    Shores MM, Biggs ML, Arnold AM, Smith NL, Longstreth WT Jr, Kizer JR, et al. Testosterone, dihydrotestosterone, and incident cardiovascular disease and mortality in the cardiovascular health study. J Clin Endocrinol Metab. 2014;99(6):2061–8.PubMedPubMedCentralCrossRefGoogle Scholar
  225. 225.
    Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab. 2012;97(6):2050–8.PubMedCrossRefGoogle Scholar
  226. 226.
    Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol. 2013;169(6):725–33.PubMedCrossRefGoogle Scholar
  227. 227.
    Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci. 2005;60(11):1451–7.PubMedCrossRefGoogle Scholar
  228. 228.
    Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Bolona ER, Sideras K, et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;82(1):29–39.PubMedCrossRefGoogle Scholar
  229. 229.
    Fernandez-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95(6):2560–75.PubMedCrossRefGoogle Scholar
  230. 230.
    Toma M, McAlister FA, Coglianese EE, Vidi V, Vasaiwala S, Bakal JA, et al. Testosterone supplementation in heart failure: a meta-analysis. Circ Heart Fail. 2012;5(3):315–21.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • Jonas Čeponis
    • 1
  • Ronald S. Swerdloff
    • 2
  • Christina Wang
    • 3
  1. 1.Department of EndocrinologyLithuanian University of Health SciencesKaunasLithuania
  2. 2.Harbor UCLA Medical Center Los Angeles, Biomedical Research InstituteTorranceUSA
  3. 3.Harbor UCLA Medical Center and Los Angeles Biomedical Research Institute, UCLA Clinical and Translational Science InstituteTorranceUSA

Personalised recommendations